Hypertension treatment update: Focus on direct renin inhibition

Journal of the American Academy of Nurse Practitioners

Volumn 23, Issue 5, 2011, Pages 239-248

  Fitzgerald, Margaret A ^a  

^a Fitzgerald Health Education Associates Inc   (United States)

Author keywords

Aliskiren; Combination therapy; Direct renin inhibitor; Epidemiology; Hypertension; Pathophysiology; Renin angiotensin aldosterone system

Indexed keywords

ALISKIREN; AMIDE; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE; RENIN;

DRUG ANTAGONISM; DRUG COMBINATION; HUMAN; HYPERTENSION; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UNITED STATES;

AMIDES; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; FUMARATES; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; RENIN; RENIN-ANGIOTENSIN SYSTEM; UNITED STATES;

EID: 79955141059     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2010.00589.x     Document Type: Review

References (77)

1. Abuissa, H., Jones, P. G., Marso, S. P., & O'Keefe, J. H., Jr. (2005). Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trials. Journal of the American College of Cardiology, 46(5), 821-826.
2. Adler, A. I., Stratton, I. M., Neil, H. A., Yudkin, J. S., Matthews, D. R., Cull, C. A., et al. (2000). Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. British Medical Journal, 321(7258), 412-419.
3. Azizi, M. (2006). Renin inhibition. Current Opinion in Nephrology and Hypertension, 15(5), 505-510.
4. Azizi, M., & Menard, J. (2004). Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation, 109(21), 2492-2499.
5. Azizi, M., Webb, R., Nussberger, J., & Hollenberg, N. K. (2006). Renin inhibition with aliskiren: Where are we now, and where are we going? Journal of Hypertension, 24(2), 243-256.
6. Bakris, G. L., Williams, M., Dworkin, L., Elliott, W. J., Epstein, M., Toto, R., et al., National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. (2000). Preserving renal function in adults with hypertension and diabetes: A consensus approach. American Journal of Kidney Diseases, 36(3), 646-661.
7. Bangalore, S., Kamalakkannan, G., Parkar, S., & Messerli, F. H. (2007). Fixed-dose combinations improve medication compliance: A meta-analysis. American Journal of Medicine, 120(8), 713-719.
8. Bangalore, S., Wild, D., Parkar, S., Kukin, M., & Messerli, F. H. (2008). Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. Journal of the American College of Cardiology, 52(13), 1062-1072.
9. Barzilay, J. I., Davis, B. R., Cutler, J. A., Pressel, S. L., Whelton, P. K., Basile, J., et al. (2006). Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine, 166(20), 2191-2201.
10. Bosch, J., Yusuf, S., Gerstein, H. C., Pogue, J., Sheridan, P., Dagenais, G., et al. (2006). Effect of ramipril on the incidence of diabetes. New England Journal of Medicine, 355(15), 1551-1562.
11. Bramlage, P., Pittrow, D., Wittchen, H. U., Kirch, W., Boehler, S., Lehnert, H., et al. (2004). Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. American Journal of Hypertension, 17(10), 904-910.
12. Brenner, B. M. (2002). Remission of renal disease: Recounting the challenge, acquiring the goal. Journal of Clinical Investigation, 110(12), 1753-1758.
13. Brown, N. J. (2008). Aldosterone and vascular inflammation. Hypertension, 51(2), 161-167.
14. Burnier, M., Brown, R. E., Ong, S. H., Keskinaslan, A., & Khan, Z. M. (2009). Issues in blood pressure control and the potential role of single-pill combination therapies. International Journal of Clinical Practice, 63(5), 790-798.
15. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jr., et al. (2003). Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42(6), 1206-1252.
16. Cleland, J. G., Abdellah, A. T., Khaleva, O., Coletta, A. P., & Clark, A. L. (2007). Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT and statins for heart failure. European Journal of Heart Failure, 9(10), 1070-1073.
17. Cutler, J. A., & Davis, B. R. (2008). Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. Circulation, 117(20), 2691-2704.
18. Dahlof, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., et al. (2002). Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): A randomised trial against atenolol. Lancet, 359(9311), 995-1003.
19. Daniels, L. B., & Maisel, A. S. (2007). Natriuretic peptides. Journal of the American College of Cardiology, 50(25), 2357-2368.
20. Dzau, V. J. (2001). Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension, 37(4), 1047-1052.
21. Ellison, D. H., & Loffing, J. (2009). Thiazide effects and adverse effects: Insights from molecular genetics. Hypertension, 54(2), 196-202.
22. Epstein, M. (2001). Aldosterone as a determinant of cardiovascular and renal dysfunction. Journal of the Royal Society of Medicine, 94(8), 378-383.
23. Farquharson, C. A., & Struthers, A. D. (2000). Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation, 101(6), 594-597.
24. Ferrario, C. M., & Levy, P. (2002). Sexual dysfunction in patients with hypertension: Implications for therapy. J Clin Hypertens (Greenwich), 4(6), 424-432.
25. Fisher, N. D., & Hollenberg, N. K. (2005). Renin inhibition: What are the therapeutic opportunities? Journal of the American Society of Nephrology, 16(3), 592-599.
26. Gradman, A. H., & Traub, D. (2007). The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension. Reviews in Cardiovascular Medicine, 8(Suppl. 2), S22-S30.
27. Grassi, G., Seravalle, G., Dell'Oro, R., Trevano, F. Q., Bombelli, M., Scopelliti, F., et al. (2003). Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study. Journal of Hypertension, 21(9), 1761-1769.
28. Hollenberg, N. K., Fisher, N. D., & Price, D. A. (1998). Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension, 32(3), 387-392.
29. Hunter, S. J., Harper, R., Ennis, C. N., Crothers, E., Sheridan, B., Johnston, G. D., et al. (1998). Effects of combination therapy with an angiotensin converting enzyme inhibitor and thiazide diuretic on insulin action in essential hypertension. Journal of Hypertension, 16(1), 103-109.
30. Jamerson, K., Weber, M. A., Bakris, G. L., Dahlof, B., Pitt, B., Shi, V., et al. (2008). Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New England Journal of Medicine, 359(23), 2417-2428.
31. Jamerson, K. A., & Basile, J. (2008). Prompt, aggressive BP lowering in high-risk patients. Journal of Clinical Hypertension, 10(1 Suppl. 1), 40-48.
32. Jandeleit-Dahm, K. A., Tikellis, C., Reid, C. M., Johnston, C. I., & Cooper, M. E. (2005). Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. Journal of Hypertension, 23(3), 463-473.
33. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. (2007). American Journal of Kidney Diseases, 49(2 Suppl. 2), S12-S154.
34. Law, M. R., Wald, N. J., Morris, J. K., & Jordan, R. E. (2003). Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. British Medical Journal, 326(7404), 1427-1434.
35. Lee, J. K., Grace, K. A., & Taylor, A. J. (2006). Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: A randomized controlled trial. Journal of the American Medical Association, 296(21), 2563-2571.
36. Lindholm, L. H., Carlberg, B., & Samuelsson, O. (2005). Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet, 366(9496), 1545-1553.
37. Liu, L., Zhang, Y., Liu, G., Li, W., Zhang, X., & Zanchetti, A. (2005). The Felodipine Event Reduction (FEVER) Study: A randomized long-term placebo-controlled trial in Chinese hypertensive patients. Journal of Hypertension, 23(12), 2157-2172.
38. Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T. B., Flegal, K., et al. (2008). Heart disease and stroke statistics-2009 update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation
39. Luna, B., & Feinglos, M. N. (2001). Drug-induced hyperglycemia. Journal of the American Medical Association, 286(16), 1945-1948.
40. Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., et al. (2007). 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 28(12), 1462-1536.
41. Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., et al. (2008). Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet, 372(9638), 547-553.
42. Margolis, K. L., Rolnick, S. J., Fortman, K. K., Maciosek, M. V., Hildebrant, C. L., & Grimm, R. H., Jr. (2005). Self-reported hypertension treatment beliefs and practices of primary care physicians in a managed care organization. American Journal of Hypertension, 18(4 Pt. 1), 566-571.
43. McKinnon, J. E., Mellors, J. W., & Swindells, S. (2009). Simplification strategies to reduce antiretroviral drug exposure: Progress and prospects. Antiviral Therapy, 14(1), 1-12.
44. Messerli, F. H. (2009). The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. Journal of the American College of Cardiology, 53(6), 468-470.
45. Messerli, F. H., & Bangalore, S. (2009). Antihypertensive efficacy of aliskiren: Is hydrochlorothiazide an appropriate benchmark? Circulation, 119(3), 371-373.
46. Messerli, F. H., Bangalore, S., & Julius, S. (2008). Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation, 117(20), 2706-2715.
47. Neutel, J. M., Smith, D. H., Weber, M. A., Schofield, L., Purkayastha, D., & Gatlin, M. (2005). Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: The Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. Journal of Clinical Hypertension, 7(11), 641-646.
48. Nussberger, J., Wuerzner, G., Jensen, C., & Brunner, H. R. (2002). Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): Comparison with enalapril. Hypertension, 39(1), E1-8.
49. Ong, K. L., Cheung, B. M., Man, Y. B., Lau, C. P., & Lam, K. S. (2007). Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension, 49(1), 69-75.
50. Paisley, K. E., Beaman, M., Tooke, J. E., Mohamed-Ali, V., Lowe, G. D., & Shore, A. C. (2003). Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney International, 63(2), 624-633.
51. Palmer, B. F. (2004). Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. New England Journal of Medicine, 351(6), 585-592.
52. Parving, H. H., Brenner, B. M., McMurray, J. J., de Zeeuw, D., Haffner, S. M., Solomon, S. D., et al. (2009). Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): Rationale and study design. Nephrology, Dialysis, Transplantation, 24(5), 1663-1671.
53. Parving, H. H., Persson, F., Lewis, J. B., Lewis, E. J., & Hollenberg, N. K. (2008). Aliskiren combined with losartan in type 2 diabetes and nephropathy. New England Journal of Medicine, 358(23), 2433-2446.
54. Patel, A., MacMahon, S., Chalmers, J., Neal, B., Woodward, M., Billot, L., et al. (2007). Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet, 370(9590), 829-840.
55. Pfeffer, M. A., McMurray, J. J., Velazquez, E. J., Rouleau, J. L., Kober, L., Maggioni, A. P., et al. (2003). Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine, 349(20), 1893-1906.
56. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., et al. (2003). Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine, 348(14), 1309-1321.
57. Pollare, T., Lithell, H., & Berne, C. (1989). A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. New England Journal of Medicine, 321(13), 868-873.
58. Pool, J. L. (2003). Is it time to move to multidrug combinations? American Journal of Hypertension, 16(11 Pt. 2), 36S-40S.
59. Roig, E., Perez-Villa, F., Morales, M., Jimenez, W., Orus, J., Heras, M., et al. (2000). Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. European Heart Journal, 21(1), 53-57.
60. Rosendorff, C., Black, H. R., Cannon, C. P., Gersh, B. J., Gore, J., Izzo, J. L., Jr., et al. (2007). Treatment of hypertension in the prevention and management of ischemic heart disease: Ascientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation, 115(21), 2761-2788.
61. Schmieder, R. E., Hilgers, K. F., Schlaich, M. P., & Schmidt, B. M. (2007). Renin-angiotensin system and cardiovascular risk. Lancet, 369(9568), 1208-1219.
62. Schmieder, R. E., Philipp, T., Guerediaga, J., Gorostidi, M., Smith, B., Weissbach, N., et al. (2009). Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: A 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation, 119(3), 417-425.
63. Shlipak, M. G., Sarnak, M. J., Katz, R., Fried, L. F., Seliger, S. L., Newman, A. B., et al. (2005). Cystatin C and the risk of death and cardiovascular events among elderly persons. New England Journal of Medicine, 352(20), 2049-2060.
64. Sica, D. A. (2002). Rationale for fixed-dose combinations in the treatment of hypertension: The cycle repeats. Drugs, 62(3), 443-462.
65. Spranger, C. B., Ries, A. J., Berge, C. A., Radford, N. B., & Victor, R. G. (2004). Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension. American Journal of Medicine, 117(1), 14-18.
66. Stanton, A., Jensen, C., Nussberger, J., & O'Brien, E. (2003). Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension, 42(6), 1137-1143.
67. Tami, L., Bair, H. T., May, M., Prescott, F., Anderson, J. L., Horne, B. D., et al. (2009). Association between baseline levels of plasma renin activity and risk of cardiovascular events. Paper presented at the American College of Cardiology, Orlando, Fl
68. Tatti, P., Pahor, M., Byington, R. P., Di Mauro, P., Guarisco, R., Strollo, G., et al. (1998). Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care, 21(4), 597-603.
69. Taylor, A. A. (2004). Combination drug treatment of hypertension: Have we come full circle? Current Cardiology Reports, 6(6), 421-426.
70. Tesfaye, S., Chaturvedi, N., Eaton, S. E., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., et al. (2005). Vascular risk factors and diabetic neuropathy. New England Journal of Medicine, 352(4), 341-350.
71. Top, C., Cingozbay, B. Y., Terekeci, H., Kucukardali, Y., Onde, M. E., & Danaci, M. (2002). The effects of valsartan on insulin sensitivity in patients with primary hypertension. Journal of International Medical Research, 30(1), 15-20.
72. Turnbull, F. (2003). Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet, 362(9395), 1527-1535.
73. Vasan, R. S. (2006). Biomarkers of cardiovascular disease: Molecular basis and practical considerations. Circulation, 113(19), 2335-2362.
74. Vitale, C., Mercuro, G., Castiglioni, C., Cornoldi, A., Tulli, A., Fini, M., et al. (2005). Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovascular Diabetology, 4, 1-8.
75. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., & Dagenais, G.; The Heart Outcomes Prevention Evaluation Study Investigators. (2000). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New England Journal of Medicine, 342(3), 145-153.
76. Yusuf, S., Teo, K. K., Pogue, J., Dyal, L., Copland, I., Schumacher, H., et al. (2008). Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine, 358(15), 1547-1559.
77. Zillich, A. J., Garg, J., Basu, S., Bakris, G. L., & Carter, B. L. (2006). Thiazide diuretics, potassium, and the development of diabetes: A quantitative review. Hypertension, 48(2), 219-224.